Tirzepatide's weight-loss curve tends to flatten between weeks 60 and 72 in published trials. Retatrutide's did not — TRIUMPH-1 reported weight loss still deepening at 104 weeks. That gap is the reason the "how do I move from one to the other" question keeps surfacing, and it is a question the trial literature does not answer directly: no published study enrolled tirzepatide-experienced participants and titrated them onto retatrutide.
What does exist is pharmacokinetic data on both compounds, published titration schedules from the retatrutide trials, and a large body of self-reported community protocols. This article separates those three sources, because they disagree on the two decisions that matter — how long to leave between compounds, and where to restart the dose ladder.
Research-context information only. Compounds discussed below are research peptides; retatrutide is an investigational drug not approved by the FDA, and tirzepatide is the active ingredient in FDA-approved finished products but is discussed here in its research-compound form. Protocols, doses, and reactions reported come from published clinical trials and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
The Two Decisions, Side by Side
| Decision | What the trial data says | What community sources report |
|---|---|---|
| Gap between compounds | Not studied. Tirzepatide t½ ≈ 5 days; ~97% cleared by day 25 | 7-14 days most commonly described; some report no gap with a low retatrutide start |
| Retatrutide starting dose | 2 mg or 4 mg weekly; 2 mg start reduced GI events (Jastreboff 2023) | 0.25-0.5 mg/week, well below the trial floor |
| Escalation pace | 4-week steps to 12 mg over 24 weeks | 8-12 weeks to reach 1.5-4 mg/week |
| Time to steady state | ~4-5 weeks at a fixed dose (t½ ≈ 6 days) | Same — reported as the "it kicked in around week 5" pattern |
The single largest discrepancy is dose. The retatrutide Phase 2 floor was 2 mg weekly. Widely circulated community protocols sit at roughly one-quarter to one-eighth of that. Anyone reading a "starting dose" figure online is likely reading one of these two numbers without being told which.
Why the Switch Is Attractive on Paper
Tirzepatide is a dual agonist: GLP-1 and GIP. Retatrutide adds a third target, the glucagon receptor, which is associated with increased energy expenditure rather than appetite suppression alone. The receptor overlap is the reason a switch is not the same as starting a metabolic peptide from scratch — two of three targets are already familiar territory.
The efficacy separation across trials is large, though it comes from separate studies rather than a head-to-head design:
| Compound | Trial | Duration | Mean weight loss | Receptors |
|---|---|---|---|---|
| Retatrutide 12 mg | TRIUMPH-1 | 80 wk | 28.3% | GIP + GLP-1 + glucagon |
| Retatrutide 12 mg | TRIUMPH-1 extension | 104 wk | 30.3% | GIP + GLP-1 + glucagon |
| Retatrutide 12 mg | Phase 2 (Jastreboff 2023) | 48 wk | 24.2% | GIP + GLP-1 + glucagon |
| Tirzepatide 15 mg | SURMOUNT-1 (Jastreboff 2022) | 72 wk | 22.5% | GIP + GLP-1 |
Those figures come from different populations, durations, and endpoints, so the ~6-point gap between TRIUMPH-1 and SURMOUNT-1 is not a measured margin. TRIUMPH-5, the first randomised head-to-head comparison of the two compounds, has not reported. Until it does, every published retatrutide-versus-tirzepatide number is a cross-trial estimate. Our full retatrutide vs tirzepatide breakdown covers where those comparisons hold up and where they do not.
The Washout Question: What Half-Lives Actually Imply
Tirzepatide has an elimination half-life of approximately 5 days. Retatrutide's is approximately 6 days per the Phase 2 pharmacokinetic data. Neither number is disputed, but they get applied to the transition question in two incompatible ways.
Full-clearance reading. Five half-lives is the conventional threshold for a drug being effectively gone — about 25 days for tirzepatide. Waiting that long means roughly three and a half weeks with no active compound, during which appetite regulation returns to baseline. Weight regain during GLP-1-class discontinuation is well documented, and this is the window where it is reported.
Partial-clearance reading. After 7 days, roughly 62% of a tirzepatide dose has cleared; after 14 days, roughly 86%. Community-reported transitions cluster in this range. The stated logic is that residual tirzepatide provides bridging appetite suppression while retatrutide climbs toward steady state — which, at a 6-day half-life, takes 4 to 5 weeks at a fixed dose.
The trade-off is symmetrical and there is no trial that resolves it. A short gap means overlapping GLP-1 and GIP agonism from two compounds simultaneously, and the commonly reported consequence is amplified gastrointestinal load in the first two weeks. A long gap means a hunger rebound before the new compound is doing anything measurable.
One detail that is frequently missed: retatrutide's approach to steady state is unaffected by how tirzepatide was handled. Whether the gap is 0 days or 25, retatrutide at a fixed weekly dose still needs 4-5 weeks to plateau. The transition period is defined by retatrutide's onset, not by tirzepatide's exit.
Where the Dose Ladder Restarts
The instinct after a year at tirzepatide 12.5-15 mg is to enter retatrutide somewhere equivalently high. Nothing in the published record supports a milligram-for-milligram conversion — the compounds are not equipotent, and the glucagon-receptor component has no tirzepatide analogue to have built tolerance against.
Published retatrutide titration, Phase 2 obesity trial:
| Phase | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2 mg or 4 mg weekly | 2 mg start reduced GI adverse events vs 4 mg |
| Weeks 4-8 | 4 mg weekly | — |
| Weeks 8-12 | 8 mg weekly | — |
| Weeks 12-48 | 12 mg weekly | Produced 24.2% weight loss at 48 weeks |
TRIUMPH-1 randomised participants to fixed 4 mg, 9 mg, or 12 mg arms. Discontinuation for adverse events tracked dose closely: 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, against 4.9% for placebo. The 4 mg arm still produced 19.0% mean weight loss at 80 weeks with a dropout rate below placebo — which is why community sources and trial commentary often describe 4 mg as the tolerability-weighted option rather than a token dose.
Community-reported protocols run substantially lower, typically 0.25-0.5 mg weekly at the start, escalating to 1.5-4 mg over 8-12 weeks, often split across two or three injections to blunt peak-concentration side effects. That range sits below the 4 mg threshold Rosenstock et al. identified as the minimum for meaningful glycaemic effect in type 2 diabetes, which is a real distinction if metabolic markers rather than weight are the endpoint of interest. Our retatrutide dosing guide carries the full titration math and the split-dose arithmetic.
Ready to buy? Compare ranked retatrutide vendors on price per mg, COA availability, and current discount codes.
